Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
46.51
+0.23 (0.50%)
At close: Jan 16, 2026, 4:00 PM EST
46.21
-0.30 (-0.65%)
Pre-market: Jan 20, 2026, 4:23 AM EST
Vera Therapeutics Employees
Vera Therapeutics had 112 employees as of December 31, 2024. The number of employees increased by 61 or 119.61% compared to the previous year.
Employees
112
Change (1Y)
61
Growth (1Y)
119.61%
Revenue / Employee
n/a
Profits / Employee
-$2,249,491
Market Cap
3.30B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 112 | 61 | 119.61% |
| Dec 31, 2023 | 51 | 5 | 10.87% |
| Dec 31, 2022 | 46 | 29 | 170.59% |
| Dec 31, 2021 | 17 | 9 | 112.50% |
| Dec 31, 2020 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VERA News
- 6 days ago - Vera Therapeutics, Inc. (VERA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - FDA Fast-Tracks Vera's At-Home Kidney Drug - Benzinga
- 13 days ago - Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy - GlobeNewsWire
- 13 days ago - Wells Fargo sees short squeeze ahead: here are three stocks to play it - Invezz
- 5 weeks ago - Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewsWire
- 6 weeks ago - Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - GlobeNewsWire
- 6 weeks ago - Vera Therapeutics, Inc. (VERA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha